The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$296.44

Today's change-4.04 -1.34%
Updated May 29 4:27 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

TSX: VRX
Delayed quote

$296.44

Today's change-4.04 -1.34%
Updated May 29 4:27 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc down $4.04

Valeant Pharmaceuticals International Inc closed lower Friday, dropping $4.04 or 1.34% to $296.44. Over the last five days, shares have gained 1.65% and are currently 3.78% off of the 52-week high. Shares have outperformed the S&P TSX by 108.66% during the last year.

Key company metrics

  • Trailing P/E80.61×
  • P/E 1 year forward28.10×
  • Forward PEG1.05×
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS$3.68
Updated May 29 4:27 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.62%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue2,1912,2802,0562,041
Total other revenue--------
Total revenue2,1912,2802,0562,041
Gross profit1,6161,6901,4951,456
Total cost of revenue575590561586
Total operating expense1,6681,6721,3721,686
Selling / general / administrative574525504516
Research & development56595967
Depreciation / amortization36586393366
Interest expense (income), net operating--------
Unusual expense (income)9240687153
Other operating expenses, total67-2320
Operating income523608684355
Interest income (expense), net non-operating-298-225-258-241
Gain (loss) on sale of assets--------
Other--------
Income before tax155590377121
Income after tax75534276122
Income tax, total8156100-1
Net income74535275126
Total adjustments to net income--------
Net income before extra. items74535275126
Minority interest-11-14
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items74535275126
Inc. avail. to common incl. extra. items74535275126
Diluted net income74535275126
Dilution adjustment00----
Diluted weighted average shares343342341341
Diluted EPS excluding extraordinary itemsvalue per share0.211.560.810.37
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.342.821.010.67